Kala Bio Inks Letter Of Intent With Virotek To Discuss Potential Deal To Appoint Kala As Exclusive Distributor, Reseller Of Virotek;s Genetic Testing, Screening Program In U.S. For Ophthalmological Indications
Kala Bio, Inc. (Nasdaq: KALA) ("Kala") and Virotek Inc. ("Virotek"), a CLIA-registered precision health and clinical genomics company, today announced that they have entered into a letter of intent (the
Kala Bio and another company are talking about a deal where Kala would sell genetic eye tests in the U.S. This shows Kala is trying to grow its business, but the deal isn't final yet—they're just in early conversations.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.